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Emerging evidence has shown that microRNA plays an important role in tumor development and
progression. Here, we report that miR-106a is frequently up-regulated in gastric cancer tissues
and positively correlates with metastasis. Restrained expression of miR-106a in gastric cancer cells
signiﬁcantly reduces their capacity of proliferation, migration and invasion. In tissue sections, the
positive signal of miR-106a localized in metastasis-associated regions conﬁrmed this result. More-
over, we show that TIMP2 is a direct downstream target for miR-106a and knockdown of TIMP2
strengthens the beneﬁcial effects of miR-106a. Our study adds miR-106a to the complex mecha-
nisms of tumor metastasis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer possesses the fourth highest incidence of human
malignant disease and causes the second highest cancer-related
death worldwide [1]. Although the research on gastric cancer has
made a great advancement, the molecular mechanisms underlying
cancer invasion and metastasis are still poorly understood.
MicroRNAs (miRNAs) is a small non-coding RNAs that nega-
tively regulates gene expression at post-transcriptional and trans-
lational levels through binding to complementary sequences in the
30-untranslated regions of their target mRNAs, and is consequently
considered to be an important regulator in many human biological
processes including human growth and development, cellular
differentiation, adhesion, angiogenesis and inﬂammation [2–4].
Recently, many ectopic expressed miRNAs have been reported to
be involved in the initiation and progression of gastric cancer as
characters of novel proto-oncogene and tumor-suppressor gene
[5]. miR-106a, which is a member of miR-17 family, is mapped
to human chromosome Xq26.2 and is derived from the precursor
miR-106a363. The mature miR-106a is highly expressed in
malignant tumors that localized in the digestive tract such asgastric cancer [6,7], esophageal cancer [8] and colorectal cancer
[9], etc. Moreover, many studies also indicate that miR-106a has
a very wide distribution so that it can be easily detected in tumor
tissues, blood [10], fecal [11] and gastric juice [12]. Despite miR-
106a harbors a valuable clinical application, the biological function
of miR-106a in gastric cancer metastasis remains obscure.
In this study, we demonstrate that miR-106a is frequently
up-regulated in human gastric cancer and closely associated with
tumor local invasion and distant spread. Furthermore, we identify
that miR-106a has a potential to become a novel metastasis-re-
lated gene by directly regulating the functional target TIMP2.
2. Materials and methods
2.1. FFPE samples and cell lines
FFPE samples were collected from General Hospital of Ningxia
Medical University with the approval of local ethics committee.
Pathological diagnosis was carried out according to the World
Health Organization criteria. Exclusion criteria were a previous his-
tory of radiotherapy and chemotherapy. Well-, moderately and
poorly differentiated human gastric cancer cells MKN-28, SGC-
7901 and BGC-823 as well as normal gastric epithelial cell GES-1
were all obtained from the Type Culture Collection of the Chinese
Academy of Sciences, Shanghai, China. Cells were maintained in
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serum (Gibco) cultured at 37 C in a 5% CO2 incubator.
2.2. RNA isolation and real-time PCR
RNA from FFPE samples and cultured cells was extracted by
RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion) and High
Pure miRNA Isolation Kit (Roche) based on the company’s speciﬁ-
cations, respectively. For detection of miRNA expression, cDNA
was obtained from 10 ng RNA using Taqman MicroRNA Assays
(Applied Biosystems) and subsequently ampliﬁed by TaqMan Uni-
versal Master Mix II (Applied Biosystems) with U6 snRNA as an
internal reference. For detection of mRNA expression, cDNA was
prepared from 300 ng RNA using PrimeScript RT Master Mix (Taka-
ra) and then quantiﬁed by SYBR Premix Ex Taq™ II (Takara) with
GAPDH as an internal control. The primers for TIMP2 were: for-
ward 50-AGCACCACCCAGAAGAAGAG-30, reverse 50-GTGACCCAGTC
CATCCAGAG-30. All experiments were performed in triplicates
where 244Ct was regarded as the analytic formula.
2.3. Transfection
Hsa-miR-106a inhibitor, antagomir and negative control were
synthesized by RiboBio (China). Small interfering RNA against
TIMP2 and negative control were designed by Genepharma
(China). The sequences of the si-TIMP2 were: sense 50-
GGCCUGAGAAGGAUAUAGATT-30, antisense 50-UCUAUAUCCUUCU-
CAGGCCTT-30. Transfection was carried out using Lipofectamine
2000 (Invitrogen) method. The ﬁnal concentration was 200 nm
for inhibitor or antagomir and 100 nm for siRNA.
2.4. MTT assay
Cell proliferation was measured by MTT assay. Cells were
seeded in 96-well culture plates at a density of 6  103 cells/well.
Transfection was performed the next day at the concentration
described above. Cell proliferation was analyzed at 24, 48, 72 and
96 h, and the optical absorbance was read at 490 nm by EnSpire
Multimode Plate Reader (PerkinElmer).
2.5. Transwell assay
Cell migration and invasion were assessed using transwell
assay. For migration, 2  104 cells in serum-free medium were
seeded into the top chambers of an insert (8 lm pore size, Merck
Millipore), which were soaked into the bottom chambers ﬁlled
with complete medium. For invasion, the same density of cells
was placed into the upper chambers, which were pre-coated with
Matrigel (BD Biosciences). After 24 h of incubation, the chambers
were ﬁxed with 4% paraformaldehyde and then stained with 0.1%
crystal violet. The cells passing through the ﬁlm were counted
under microscope.
2.6. In situ hybridization
The expression and, more importantly, location of miR-106a
was achieved by in situ hybridization (ISH). FFPE specimens were
deparafﬁnized followed by rehydration and digestion with 15 lg/
ml proteinase K (Exiqon) at 37 C for 10 min. The slides were
hybridized with 40 nM double-digoxigenin labeled locked nucleic
acid (LNA) probe (Exiqon) at 55 C for 1 h. The anti-Digoxigenin-
AP was applied at 1:800 (Roche) for 60 min at room temperature.
The colorimetric reaction was performed using BCIP/NBT ready-
to-use tablets (Roche). Neutral Red Staining Solution (Sigma–Al-
drich) was used for nuclear counter staining. The miR-106aappeared as dark blue particles in the cytoplasm or nucleus after
staining.
2.7. Luciferase reporter assay
The 30-UTR of TIMP2 (NM_003255.4) containing the predicted
miR-106a binding site was constructed by RiboBio (China). The
mutant TIMP2 30-UTR was created by mutating multiple nucleo-
tides complementary to the miR-106a seed region. HEK293T cells
were cultured in 96-well plates with 50–70% conﬂuence 24 h
before transfection. A mixture of 100 ng pmiR-RB-Report™ h-
TIMP2 wild type (WT) or mutant (Mut) reporter plasmid vector
together with 50 nM hsa-miR-106a mimics or negative control
(RiboBio) were co-transfected. The luciferase activity was mea-
sured 48 h post-transfection using Dual-Glo Luciferase Assay Sys-
tem (Promage) with Renilla (Rluc) luciferase activity as the
reporter gene and ﬁreﬂy luciferase (Luc) as the reference gene.
2.8. Western blot
Whole-cell proteins were collected with RIPA Buffer (Pierce)
and separated by 12% SDS–PAGE before transfer. The PVDF mem-
brane (Merck Millipore) was blocked with 5% non-fat milk and
incubated with rabbit anti-TIMP2 monoclonal antibody (1:1000,
Abcam). A b-Actin antibody (Santa Cruz Biotechnology) was used
as control for normalization. The results were obtained by Immobi-
lon™Western Chemiluminescent HRP Substrate (Merck Millipore).
2.9. Statistical analysis
Statistical analysis was performed using SPSS statistics 17.0.
The results were expressed as mean ± S.E.M. and the level of signif-
icance was set at P < 0.05. Expression of miR-106a was determined
by paired T-test, the relationship between miR-106a and clinico-
pathologic parameters was compared using independent sample
T-test and One-Way ANOVA, as well as the results of cellular
experiments.
3. Results
3.1. RNA from FFPE samples has appropriate quantity and quality
To determine whether or not RNA from FFPE samples was suit-
able for downstream applications, we examined the RNA quantity
and quality. The total RNA purity in 82 cases of FFPE samples was
2.022 ± 0.190, and the concentration was 267.062 ± 210.435, indi-
cating that FFPE samples can yield enough total RNA for most
applications. The integrity check showed that RNA from FFPE sam-
ples was typically recovered as a smear, except in higher quality
preparations, which yielded two broad bands representing 18s
and 28s rRNA. A majority of the smeared RNA samples ranged from
200 to 300 bases. Moreover, we monitored the effects on PCR efﬁ-
ciency by amplifying the fragments of small sizes (106 bp) from
the highly expressed house-keeping gene U6 snRNA. The results
showed that this fragment could be ampliﬁed without any abnor-
mity and it also had a stable expression in coupled FFPE samples
(P = 0.216) (data not shown).
3.2. miR-106a is up-regulated in gastric cancer
To examine the expression of miR-106a at different levels, we
designed a paired sample containing 41 gastric cancer and adjacent
non-tumor tissues. As shown in Fig. 1A, the miR-106a expression
was signiﬁcantly up-regulated in gastric cancer tissues when com-
pared with the corresponding non-tumor samples with the fold
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Fig. 1. miR-106a is up-regulated in gastric cancer tissues and cells. (A) qRT-PCR for miR-106a in 41 paired human gastric cancer tissues and adjacent non-tumor tissues.
⁄P = 0.000. (B) qRT-PCR for the enhanced expression of miR-106a in 85.37% (35/41) of tumor tissues. (C) qRT-PCR for miR-106a in three different gastric cancer cells and GES-1
cell. ⁄P = 0.000.
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expression level of miR-106a in tumor tissues was higher than that
in normal tissues (P = 0.000). As shown in Fig. 1B, enhanced miR-
106a was observed in 85.37% (35/41) of tumor tissues, indicating
that up-regulation of miR-106a was a frequent event in human
gastric cancer. In addition, different differentiated tumor cells were
also selected to investigate the effects of miR-106a. As shown in
Fig. 1C, the expression of miR-106a varied in the three cells
(P = 0.000). Compared with GES-1 cell, the expression of miR-
106a in SGC-7901 and BGC-823 cells were both signiﬁcantly up-
regulated with the fold change of 2.50 ± 0.18 and 2.45 ± 0.23
(P = 0.000), unlike the MKN-28 cell with the fold change of
0.96 ± 0.20 (P = 0.714).
3.3. Relationship between miR-106a and clinical pathology of gastric
cancer
It was revealed in Table 1 that the over-expression of miR-106a
was closely associated with the clinicopathological parameters of
gastric cancer. In our group, the expression of miR-106a did not
have signiﬁcant correlation with patients’ age, gender, tumor loca-
tion, size, degree of differentiation and nerves involvement, but
was positively with lymph node metastasis (P = 0.002), vascular
invasion (P = 0.017) and depth of inﬁltration (P = 0.009). These data
indicated that the over-expressed miR-106a would create greater
opportunities to develop not only local invasion but also distant
spread.
3.4. Ectopic miR-106a has a diverse effect on cell proliferation
To estimate the potential role of miR-106a in gastric cancer, we
constructed the sequence-speciﬁc inhibitor for hsa-miR-106a and
compared its performance on four different cells. On the basis of
results above, we found that in contrast to negative group, the pro-
liferations of SGC-7901 and BGC-823 cells with enhanced expres-
sion of miR-106a were attenuated when miR-106a inhibitor was
used. However, under the same treatment, MKN-28 cell withsilenced expression of miR-106a and normal GES-1 cell were not
express signiﬁcant difference. (Fig. 2).
3.5. Ectopic miR-106a triggers cell migration and invasion
In FFPE samples, we found that the markedly expressed miR-
106a may lead to the enhancement of gastric cancer metastasis.
To gain insight into the biological functions of miR-106a, we con-
ducted transwell assays which indicated that in SGC-7901 and
BGC-823 cells infected with miR-106a inhibitor, migration
(16.35 ± 12.44 vs. 49.05 ± 27.63, P = 0.000; 18.80 ± 17.01 vs.
94.23 ± 18.15, P = 0.000) and invasion (14.25 ± 9.13 vs.
35.20 ± 25.55, P = 0.000; 16.15 ± 8.42 vs. 83.00 ± 42.81, P = 0.000)
were both profoundly decreased compared with negative group,
but the similar performance was not present in MKN-28, that
was, supplanted by no change both in migration (P = 0.224) or
invasion (P = 0.374) (Fig. 3). GES-1 per se did not have metastatic
potential, even upon induction by miR-106a. The results from gas-
tric cancer cells approved the conclusion from gastric cancer tis-
sues that miR-106a was highly associated with tumor metastasis.
3.6. Localization of miR-106a conﬁrmed its relationship with
metastasis
The ﬁndings above illustrated that miR-106a expression was
correlated with gastric cancer metastasis such as depth. In order
to catch the phenomenon more directly, we employed in situ
hybridization to localize gene expression. Since we wanted to mark
sure that miR-106a did promote tumor inﬁltration, it needed a sec-
tion on which metastasized tumors and tumors that had not yet
occurred metastasis were both involved. In view of this, we chose
advanced gastric cancer tissues and the results demonstrated that
the predominant expression of miR-106a in the endovascular inva-
sion of gastric cancer cells inﬁltrating into the muscular and serous
layers as intravascular emboli. On the contrary, it was less
expressed in mucosal surface. (Fig. 4) The result conﬁrmed the
relationship between miR-106a and tumor metastasis.
Table 1
miR-106a expression and clinical pathology of gastric cancer.
Characteristics No. of patients % miR-106a (average fold change ± SD) P-value
Age (years)
P50 32 78 3.009 ± 1.8464 0.941
<50 9 22 3.067 ± 2.6935
Sex
Male 29 71 2.752 ± 1.6932 0.187
Female 12 29 3.675 ± 2.6327
Tumor site
Cardia 9 22 4.356 ± 2.2528 0.078
Body 6 15 2.767 ± 2.0801
Antrum 26 63 2.619 ± 1.7989
Tumor size (cm)
T 6 2 10 24 2.230 ± 1.5144 0.126
2 < T 6 5 19 46 3.637 ± 2.2916
T > 5 8 20 2.113 ± 1.7324
Miss 4 10 3.900 ± 1.2138
Differentiation
Well 2 5 0.550 ± 0.3536 0.206
Moderate 23 56 3.209 ± 1.9329
Poor 16 39 3.063 ± 2.1351
Lymph node
Positive 24 59 3.800 ± 2.1452 0.002⁄
Negative 17 41 1.924 ± 1.1956
Vessels
Positive 11 27 4.245 ± 2.1815 0.017⁄
Negative 30 73 2.573 ± 1.7971
Nerves
Positive 2 5 3.350 ± 0.2121 0.818
Negative 39 95 3.005 ± 2.0741
Depth
Mucosa 4 10 1.200 ± 0.5292 0.009⁄
Submucosa 4 10 1.600 ± 0.3559
Muscular layer 9 22 2.244 ± 0.7091
Serous layer 24 58 3.854 ± 2.2368
* Indicated statistical signiﬁcance (P < 0.05).
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Fig. 2. miR-106a regulates human gastric cancer cell proliferation in vitro. MTT assays after transduction with miR-106a inhibitor or negative control in four gastric cells.
⁄P < 0.05, ⁄⁄P < 0.001.
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Fig. 3. miR-106a promotes human gastric cancer cell migration and invasion in vitro. Transwell migration (A) and invasion (B) assays after transduction with miR-106a
inhibitor or negative control in three gastric cancer cells. ⁄P = 0.000.
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Fig. 4. LNA-ISH detection of miR-106a in FFPE tissues from moderately differentiated human gastric adenocarcinoma. (A) Glands inﬁltrated into the deep gastric wall.
(Magniﬁcation 40) (B) Strong miR-106a staining in the inﬁltrated glands. (Magniﬁcation 100) (C and D) The glands with positive signals concentrated on the vascular
cavity. (Magniﬁcation 400) ISH-positive signals stain blue, whereas nuclei stain red.
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Three open access programs—TargetScan, miRDB and miRan-
da—to predict the target of miR-106a. TIMP2, which was one of
the metastasis-associated genes, was selected for analysis
(Fig. 5A). The 30-UTR reporter of TIMP2 containing wild and mutant
sequences was cloned. When the wild type was transfected with
miR-106a mimics and negative, the luciferase activity of WT/
miR-106a was signiﬁcantly decreased compared with WT/NC
(P = 0.000). When the mutant TIMP2 was transfected with miR-
106a mimics and negative, no signiﬁcant difference can be seen
between Mut/miR-106a and Mut/NC (P = 0.323) (Fig. 5B). Western
blot demonstrated that miR-106a inhibition in SGC-7901 and BGC-
823 cells elevated TIMP2 protein level compared with control
group (Fig. 5C). To further attest the negative relationship between
miR-106a and target gene TIMP2, we measured TIMP2 mRNA and
protein levels in gastric cancer cells. Data displayed in Fig. 5D and E
showed that the expression of TIMP2 in gastric cancer cells was
generally lower. The relative expression in MKN-28, SGC-7901
and BGC-823 was 0.74 ± 0.01 (P = 0.007), 0.26 ± 0.08 (P = 0.000),
0.17 ± 0.02 (P = 0.000), respectively. These evidences deduced that
under-expression of TIMP2 may result from up-expression of miR-
106a.
3.8. Knockdown of TIMP2 promotes cell proliferation, migration and
invasion
Since we had observed that miR-106a could meditate gastric
cancer SGC-7901 and BGC-823 cells migration and invasion, a
speciﬁc siRNA should be introduced into these two cells toA  
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HEK293T cells with wild-type or mutant TIMP2 30-UTR vectors and miR-106a mimic or ne
after infection with miR-106a antagomir or negative control. b-Actin is a loading control. (
cell. b-Actin is a loading control. ⁄P = 0.007, ⁄⁄P = 0.000.determine whether down-regulation of TIMP2 had a phenocopy
of over-expression of miR-106a. When interference was imple-
mented, the expression level of TIMP2 in SGC-7901 and BGC-823
cells was sharply down (P = 0.000) (Fig. 6A). Moreover, silencing
of TIMP2 accelerated cell proliferation of high-grade gastric cancer
(Fig. 6B). Migration (58.39 ± 9.24 vs. 39.31 ± 7.31, P = 0.000;
82.13 ± 7.30 vs. 66.30 ± 3.55, P = 0.000) and invasion
(45.00 ± 11.58 vs. 32.96 ± 3.95, P = 0.000; 81.20 ± 14.20 vs.
65.36 ± 3.74, P = 0.000) were also increased in SGC-7901 and
BGC-823 cells compared with negative group, respectively
(Fig. 6C). These change suggested that inhibition of TIMP2 expres-
sion could mimic the effect of miR-106a. Negative regulation of
TIMP2 by miR-106a was, at least in part, responsible for miR-
106a-induced gastric cancer cell progression.
4. Discussion
In this study, we focused on miR-106a and used qualitative,
quantitative and positioning analysis to investigate its biological
functions in gastric cancer. To take full advantage of existing
resources, archived FFPE samples were selected. From our experi-
ments, miRNA in FFPE samples was preserved perfectly and can
be ampliﬁed successfully. The results verify an overview that miR-
NA species are less affected by autolysis, cross linking and frag-
mentation during FFPE preparation [13,14]. Above all, we found
that the frequently up-regulated miR-106a positively adjusted
gastric cancer cell proliferation, migration and invasion. Similarly,
miR-17 was found to promote gastric cancer proliferation [15].
As described previously, miR-17 and miR-106a belong to the same
family, with the results indirectly corroborating the promotionalgauggacgugacauuCGUGAAAa
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Fig. 6. Knockdown of TIMP2 promotes cell proliferation, migration and invasion in vitro. (A) qRT-PCR for TIMP2 in SGC-7901 and BGC-823 cells transfected with si-TIMP2 or
negative control. ⁄P = 0.000. (B) MTT assay in SGC-7901 and BGC-823 cells after siRNA transfection. ⁄P < 0.05, ⁄P < 0.001. (C) Transwell assay after interference. ⁄P = 0.000.
606 M. Zhu et al. / FEBS Letters 588 (2014) 600–607effect of miR-106a. Because the capability of cell migration and
invasion is considered to be the most important determinant in
the process of cancer metastasis, we perform several methods to
visualize miRNA expression and localization in this course. One
of the powerful techniques is LNA-ISH, which offers a spatially
accurate resolution of miRNA expression unsurpassed by others
[16,17]. Using this LNA-modiﬁed probe, we found that the positive
miR-106a signals appeared exactly in tumor embolus, deep inside
the muscular layer. Given the fact that over-expressed miR-106a
does promote tumor progression and has a potential to act as a
new metastasis-related gene in gastric cancer.Metastasis is a complicated process that refers to multiple fac-
tors and multiple steps [18,19]. Our work elucidates the underlying
mechanism of miR-106a in gastric cancer metastasis that is not ex-
plored as yet. The exploration of the target genes for clariﬁcation of
the disorder lead to the identiﬁcation of TIMP2 which is a member
of tissue inhibitor of metallopeptidases (TIMPs) family as a direct
and functional downstream mediator for miR-106a. TIMPs family
are natural inhibitors of matrix metalloproteinases (MMPs), which
can degrade the extracellular matrix (ECM) and basement mem-
brane (BM), the degradation of which is a prerequisite for tumor
metastasis [20]. It has been reported that TIMP2 combines with
M. Zhu et al. / FEBS Letters 588 (2014) 600–607 607activated MMP2 through 1 to 1 non-covalent forms and abrogates
its collagenases and gelatinases activity, reduces the degradation of
ECM, and maintains the integrity of BM [21]. In addition to an
inhibitory role against metalloproteinases, TIMP2 has a unique role
among TIMP family members in its ability to directly suppress the
proliferation of endothelial cells with MMP-independent mode
[22]. Herein, we show that miR-106a may cooperate with TIMP2
to start gastric cancer invasion-metastasis cascade reaction. The
up-regulation of miR-106a may exert oncogenic role with promot-
ing effects on cell proliferation and especially metastasis by target-
ing TIMP2, and conversely, knockdown of TIMP2 could mimic the
miR-106a-induced cancer development beneﬁts. These discoveries
prove our speculation that in many gastric cancer types, there is
prevalently elevated miRNAs such as miR-106a, which always
situated in the upstream direct against anti-metastatic gene like
TIMP2 and suppresses its expression at post-transcriptional levels;
the regulated target gene subsequently facilitates the tumor cell
dissemination. Inverse correlation of miR-106a and TIMP2
ultimately contributes to the enhancement of gastric cancer
progression.
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